Patent classifications
G01N2333/9128
SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST EBOLA VIRUS
This invention provides compositions and methods to treat a condition or disease without the use of exogenous targeting sequences or chemical compositions. The present invention relates to single-domain antibodies (sdAbs), proteins and polypeptides comprising the sdAbs that are directed against targets that cause a condition or disease. The invention also includes nucleic acids encoding the sdAbs, proteins and polypeptides, and compositions comprising the sdAbs. The invention includes the use of the compositions, sdAbs, and nucleic acids encoding the sdAbs for prophylactic, therapeutic or diagnostic purposes.
SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST HUMAN IMMUNODEFICIENCY VIRUS
This invention provides compositions and methods to treat a condition or disease without the use of exogenous targeting sequences or chemical compositions. The present invention relates to single-domain antibodies (sdAbs), proteins and polypeptides comprising the sdAbs that are directed against targets that cause a condition or disease. The invention also includes nucleic acids encoding the sdAbs, proteins and polypeptides, and compositions comprising the sdAbs. The invention includes the use of the compositions, sdAbs, and nucleic acids encoding the sdAbs for prophylactic, therapeutic or diagnostic purposes.
PROGRAMMABLE NUCLEASE-BASED ASSAY IMPROVEMENTS
The present disclosure describes various improvements for programmable nuclease-based detection assays. Also provided are compositions, methods, kits, systems, and devices for practicing the same. Such improvements include improved reporter designs to facilitate the cleavage of a reporter immobilized on a substrate by an activated programmable nuclease. Improved reporter designs may comprise various lengths and structures of the reporter. The substrate can also comprise immobilized guide nucleic acids and/or programmable nucleases.